Cellipont Bioservices is a leading contract development and manufacturing organization (CDMO) specializing in the development and production of advanced cell therapies. With a strong commitment to enhancing patient access to transformative medicines, Cellipont excels in providing best-in-class capabilities across various stages of clinical product development. Their team comprises experienced specialists known for successfully translating cell therapy processes from the laboratory bench to clinical applications, focusing on both autologous and allogenic therapies.

The company offers an extensive range of services, including CAR-T/TCR-T therapies, Dendritic Cells (DCs), Fibroblasts, Natural Killer (NK) cells, Mesenchymal Stem Cells (MSCs), Hematopoietic Stem Cells (HSCs), Tumor-Infiltrating Lymphocytes (TIL), and cell banking solutions. Cellipont's expertise spans from pre-clinical development to late-phase commercialization, making it a trusted partner for clients in the fast-evolving field of biotechnology. By fostering collaboration within the research and clinical communities, Cellipont is dedicated to shaping the future of innovative cell therapies.